GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Cyclically Adjusted FCF per Share

LFCR (Lifecore Biomedical) Cyclically Adjusted FCF per Share : $-0.89 (As of Feb. 2025)


View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Lifecore Biomedical's adjusted free cash flow per share for the three months ended in Feb. 2025 was $-0.115. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.89 for the trailing ten years ended in Feb. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -59.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Lifecore Biomedical was 138.10% per year. The lowest was -75.30% per year. And the median was -8.15% per year.

As of today (2025-06-24), Lifecore Biomedical's current stock price is $8.28. Lifecore Biomedical's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2025 was $-0.89. Lifecore Biomedical's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Lifecore Biomedical was 374.33. The lowest was 37.46. And the median was 59.72.


Lifecore Biomedical Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Lifecore Biomedical's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Cyclically Adjusted FCF per Share Chart

Lifecore Biomedical Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 -0.20 -0.49 -0.70 -0.81

Lifecore Biomedical Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.81 -0.81 -0.83 -0.83 -0.89

Competitive Comparison of Lifecore Biomedical's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Cyclically Adjusted Price-to-FCF falls into.


;
;

Lifecore Biomedical Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lifecore Biomedical's adjusted Free Cash Flow per Share data for the three months ended in Feb. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Feb. 2025 (Change)*Current CPI (Feb. 2025)
=-0.115/134.6241*134.6241
=-0.115

Current CPI (Feb. 2025) = 134.6241.

Lifecore Biomedical Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201505 0.217 100.333 0.291
201508 -0.192 100.548 -0.257
201511 -0.280 100.135 -0.376
201602 -0.252 100.040 -0.339
201605 0.029 101.355 0.039
201608 0.158 101.617 0.209
201611 -0.128 101.829 -0.169
201702 0.466 102.779 0.610
201705 -0.247 103.256 -0.322
201708 -0.082 103.587 -0.107
201711 -0.030 104.072 -0.039
201802 0.095 105.052 0.122
201805 -0.478 106.148 -0.606
201808 -0.437 106.383 -0.553
201811 -0.055 106.338 -0.070
201902 -0.066 106.649 -0.083
201905 -0.445 108.048 -0.554
201908 -0.529 108.245 -0.658
201911 -0.533 108.519 -0.661
202002 0.154 109.139 0.190
202005 -0.592 108.175 -0.737
202008 0.424 109.662 0.521
202011 -0.046 109.793 -0.056
202102 -0.404 110.968 -0.490
202105 -0.272 113.576 -0.322
202108 -0.241 115.421 -0.281
202111 -0.347 117.269 -0.398
202202 -0.789 119.703 -0.887
202205 -0.405 123.323 -0.442
202208 -0.151 124.958 -0.163
202211 -0.209 125.607 -0.224
202302 -0.621 126.928 -0.659
202305 -0.311 128.314 -0.326
202308 -0.440 129.538 -0.457
202311 -0.082 129.548 -0.085
202402 -0.213 130.930 -0.219
202405 0.161 132.509 0.164
202408 -0.131 132.816 -0.133
202411 -0.250 133.110 -0.253
202502 -0.115 134.624 -0.115

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Lifecore Biomedical  (NAS:LFCR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Lifecore Biomedical was 374.33. The lowest was 37.46. And the median was 59.72.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Lifecore Biomedical Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical Business Description

Traded in Other Exchanges
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
Executives
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318